Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 9c; Offers FY23 EPS Guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $248.36 --0%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.84, $0.09 worse than the analyst estimate of $4.93. Revenue for the quarter came in at $972 million versus the consensus estimate of $969.02 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2023 EPS of $18.15-$19.00, versus the consensus of $18.66.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Evogene (EVGN) Tops Q2 EPS by 15c
- Pony AI (PONY) Reports Revenue Above Estimates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
